Repligen (RGEN) drew investor attention after its second quarter 2026 report, which featured adjusted earnings and revenue above expectations, plus higher full year revenue and EPS guidance supported by broad product franchise growth.

Repligen's share price has been volatile around the results, with a 1 day share price return that declined 3.16% and a 7 day share price return that declined 2.68%, even after a 30 day share price return of 24.81% and a 1 year total shareholder return of 44.11%, which suggests that momentum has been building over a longer stretch.

Scan how Repligen's momentum and earnings beat compare with other potential opportunities by reviewing our hand picked 19 high quality undiscovered gems.

Repligen appears to be a strong business coming off an earnings beat and higher guidance, yet the stock has already moved sharply over the past quarter. Are you paying up now, or still getting fair value on quality?

Most Popular Narrative: 3.2% Undervalued

The most followed narrative puts Repligen's fair value at about $182 per share, slightly above the last close of $176.27. This frames the recent rally as still leaving some upside according to that model.

Strong and sustained order growth across biopharma, CDMO, and capital equipment segments supported by record multi-quarter book-to-bill ratios and robust funnel positions the company for above-market revenue increases as therapy pipelines expand and demand for advanced bioprocessing solutions rises.

Want to see what underpins that fair value for Repligen? The narrative leans on faster revenue expansion, margin uplift, and a rich future earnings multiple. The exact assumptions might surprise you.

Result: Fair Value of $182.05 (UNDERVALUED)

However, Repligen's reliance on funding constrained biotech customers and exposure to softer gene therapy and AAV demand could still upset those fair value assumptions.

Another View: Repligen Looks Expensive On Sales

The analyst fair value narrative presents Repligen as about 3.2% undervalued around $182 per share. On a different yardstick, the current P/S of 12.7x is much higher than the US Life Sciences industry at 4.4x, the peer average at 5x, and a fair ratio of 5.9x. That gap highlights meaningful valuation risk if sentiment or growth expectations cool from here.

Next Steps

The mixed sentiment around Repligen's valuation and outlook is clear, so act while the data is fresh and weigh both the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Repligen?

Repligen is just one opportunity on your radar. The next strong idea might come from a completely different corner of the market, so do not stop your research here.

Use the Simply Wall Street Screener to quickly surface focused ideas that match the kind of risk and return profile you actually want.

• Target potential value opportunities by scanning our curated 44 high quality undervalued stocks that combine appealing pricing with solid underlying fundamentals.
• Prioritise resilience and sleep easier at night by reviewing a 74 resilient stocks with low risk scores that filters for companies with steadier risk profiles.
• Strengthen your watchlist with a list of solid balance sheet and fundamentals (51 results) so you are not caught out by fragile finances when conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.